Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for
Duchenne muscular dystrophy and acute decompensated heart failure.
Phrixus Pharmaceuticals, Inc. reports positive preclinical results in respiratory disease in Duchenne muscular dystrophy after subcutaneous delivery of Carmeseal™ at
very low doses
Results extend the utility of Carmeseal™ from cardiac disease to respiratory disease, the main cause...
Phrixus has concurrence with FDA on the following: